Professor Nadiia Pasiechko Took Part in the 60th EASD European Congress on Diabetes in Madrid.
EASD European Congress on Diabetes was held in Madrid (Spain). Leading specialists from different countries represented the latest research and unique discoveries in diabetology.
EASD European Congress on Diabetes was held in Madrid (Spain). Leading specialists from different countries represented the latest research and unique discoveries in diabetology.
The event included thematic lectures, master classes, and discussion clubs on the influence of NZKTG-2 on various kidney functions and the functional state of the myocardium. For the first time, the effect of a new drug on liver function and prevention of diabetes in patients with insulin resistance was presented. Participants demonstrated a study of cardiovascular risks and their protection by new groups of drugs in patients with type 1 diabetes; genetic and epigenetic features of type 2 diabetes were investigated.
Many studies were presented on the effectiveness of the combination of SGLT-2 and GLP-1 drugs. An analysis of the combined use of these drugs to improve the cardio-renal-metabolic continuum has demonstrated positive effects. New drugs of the GLP-1 class were demonstrated.
Studies on the effectiveness of ultralong-acting insulins and their effect on prandial and postprandial glycemia and glycated hemoglobin were also noteworthy.
The Congress is an example of a fundamental, systemic, integrative approach to solving the problem of diabetes, introducing new treatment strategies, and developing personalized medicine.
The information received during the Congress will be used:
- during practical classes and lectures on relevant topics in endocrinology for the students of Medicine specialty;
- at scientific and practical conferences to summarize the experience of the world’s leading universities and scientific institutions regarding the latest approaches to the diagnosis, treatment, and self-monitoring of diabetes.
